Urogenital system

Bifidobacterium breve – BR03 (DSM 16604)

Constipation • Intestinal transit • Anti-inflammatory • Reduction of gastro-intestinal discomfort • Inhibition of pathogenic E. coli • Restoration of a better dietary ω-6/ω-3 balance • Conjugated linoleic acids (CLA) production • Prospective use in the treatment of obesity • Cystitis • Inhibition of E. coli • Oxalate degradation • Reduction of intestinal inflammation • Potential reduction …

Bifidobacterium breve – BR03 (DSM 16604) Read More »

Bifidobacterium breve – B632 (DSM 24706)

Inhibition of pathogens E. coli and Enterobacteriaceae

Bifidobacterium longum – BL03 (DSM 16603)

Constipation • Intestinal transit • Oxalate degradation • Reduction of intestinal inflammation • Potential reduction of kidney stones incidence

Femme

Femme is a probiotic complex by SynBalance, specifically designed to support women’s intimate health.Femme has been clinically tested to confirm the effectiveness in humans. The first clinical trial has investigated the ability of probiotic strains to colonize and persist in the vagina through oral intake. In a RDBPC trial 40 healthy women were enrolled and …

Femme Read More »

Lactobacillus acidophilus – LA02 (DSM 21717)

Rebalance of intestinal microbiota • Oxalate degradation • Reduction of intestinal inflammation • Potential reduction of kidney stones incidence

Lactobacillus delbrueckii subsp. delbrueckii – LDD01 (DSM 22106)

Gaseous colic • Inhibition of E. coli, including toxinogenic O157:H7 • Inhibition of Klebsiella pneumoniae and of different coliforms isolated from colicky infants • Inhibition of pathogens E. coli, Klebsiella and gas-producing coliforms

Lactobacillus paracasei – LPC09 (DSM 24243)

Oxalate degradation • Reduction of intestinal inflammation • Potential reduction of kidney stones incidence

Lactobacillus plantarum – LP01 (LMG P-21021)

Constipation • Intestinal transit • Leaky gut • Inhibition of E. coli• Antioxidant activity • Reduced glutathione (GSH) and superoxide dismutase (SOD) production • Cystitis • Inhibition of E. coli • Oxalate degradation • Reduction of intestinal inflammation • Potential reduction of kidney stones incidence

Lactobacillus plantarum – LP02 (LMG P-21020)

Cystitis • Inhibition of E. coli

Lactobacillus reuteri – LRE02 (DSM 23878)

Production of reuterin and vitamin B12 • Anti-pathogen activity and immunostimulation (induction of IFN-gamma) • Oxalate degradation • Reduction of intestinal inflammation • Potential reduction of kidney stones incidence

Lactobacillus rhamnosus – LR04 (DSM 16605)

Diarrhea • Inhibition of E. coli, including enterohemorrhagic O157:H7 • Cystitis • Inhibition of E. coli

Lactobacillus rhamnosus – LR06 (DSM 21981)

Inhibition of E. coli • Antioxidant activity • Reduced glutathione (GSH) and superoxide dismutase (SOD) production

Lactobacillus salivarius – CRL1328

Inhibition of Enterococcus faecalis, Enterococcus faecium and Neisseria gonorrhoeae • Vaginal health • Prevention of urogenital infections • Inhibition of Candida

Lactobacillus paracasei P 30020

Recurrent cystitis. Deposited at the Laboratorium voor Microbiologie BCCM (Gent, Belgium). Deposit N°LMG P 30020. Isolated from goat’s milk. The microbial strain is not genetically modified and it is of natural origin (OMG Reg. (CE) 1829/2003 e 1830/2003). Shelf life raw material: 12 months when stored below 8°C.